Current Investments
Okairos AG
Riccardo Cortese, Basel, CH
Okairos is a Swiss based vaccine company, with a subsidiary in Italy, developing vaccines for mutating viruses. Its innovative viral adenovirus T cell platform allows to develop novel vaccines for the prevention and treatment of major life-threatening infections, including malaria and hepatitis C. Company has entered clinical stage.
Opsona Ltd
Mark Heffernan, Dublin, Ireland
Opsona is a drug development company, focused on novel therapeutic and preventative approaches to inflammatory and related diseases. Opsona has a pipeline of therapeutics in advanced pre-clinical development which modulate the innate immune system, including biologics and small molecules that are targeting TLR-2 and Nalp-3 The company has signed some significant partnering and collaborative deals, such as with Wyeth.
Oxagen Ltd.
Mark Payton, Oxford, UK
Oxagen is a drug discovery and development company specializing in inflammation with a first in class CRTH2 antagonist programme in inflammatory and respiratory diseases.